An exploratory double-blind, placebo controlled, randomized, 12-week oral dose study to evaluate the effects of MK0736 on atherosclerotic disease biomarkers in lower extremity plaque excised from patients with peripheral arterial disease
Phase of Trial: Phase I
Latest Information Update: 05 May 2017
At a glance
- Drugs MK 0736 (Primary)
- Indications Atherosclerosis; Peripheral arterial disorders
- Focus Pharmacodynamics
- Sponsors Merck & Co
- 31 Aug 2018 Biomarkers information updated
- 25 Aug 2008 The expected completion date for this trial is now 1 Aug 2008.
- 05 Aug 2008 Actual start date changed from Dec 2008 to Aug 2008 as reported by ClinicalTrials.gov.